Article · 26 May 2026
Review articlePublished 31 May 2010
LEISHMANIASIS: Current Treatment Strategies and Future Opportunities
Abstract
Select any words in the title or abstract, or press this and choose a sentence.
Leishmaniasis, in its variety of visceral (VL), cut aneous (CL) and mucocutaneous (MCL) forms, a vector-borne parasitic disease, is caused by the infection with the obligate intracellular protozoan parasite, Leishmania, transmitted by abou t 30 species of Phlebotomine sandflies. The control of leishmaniasis remains a problem–principa lly a zoonotic infection, except in epidemics where it is anthroponotic, interruption of transmis sion is difficult, though not impossible. No vaccines exist for VL, CL or MCL and chemotherapy i s inadequate and expensive. Current regimes use pentavalent antimony as primary therapy , which must be administered parenterally. Should this fail, a number of other drugs may be em ployed, depending upon the species of Leishmania concerned and the resources available to the health professionals involved. The most widely used of these is amphotericin B, which is highly active but has extensive toxicity complications. Pentamidine and Paromomycin are used in some instances, and a new anti- leishmanial, Miltefosine, may be used in the future . In short, there remains a pressing need for new anti-leishmanials and this chapter reviews the current status of chemotherapy, the various Novel Targets and some important lead compounds in antileishmanial chemotherapy.
Subjects
Pharmaceutical SciencesChemistryAsk about this article
Answers come only from this article's title, abstract and keywords, each sentence pointing to where it comes from. Your question is sent to OpenAI to write the answer. Scholars Central does not store it.
More from this journal
The newest in Journal of Chemical and Pharmaceutical Research.
Article · 12 Mar 2025
Studies on Exploring the Efficacy of Plant Based Silver Nanoparticles in Preventing Mercuric Toxicity on Blood
Article · 10 Mar 2025
Measurement of Malondialdehyde in Plasma by High Performance Liquid Chromatography Assay in Severe Cranial Trauma at The First Week of Admission: Comatose Patients
Conferences in this field
Upcoming conferences in this field.
Follow
New articles from what you follow go into your email digest, once you agree to alert emails.
- JournalJournal of Chemical and Pharmaceutical Research
- SubjectPharmaceutical Sciences
- SubjectChemistry
- BylineArticles whose byline prints “Sachin Malik”
- BylineArticles whose byline prints “Sachin Kumar”
- BylineArticles whose byline prints “Ashish Choudhary”
- BylineArticles whose byline prints “Arun Kumar”
- BylineArticles whose byline prints “Avrendra singh”
- BylineArticles whose byline prints “Garima Avasthi”